MPG.eBooks - Search Results

1

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

2

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

3

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

4

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

5

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Canada...”

Read Now

6

Pharmacoeconomic review report: Sarilumab (Kevzara)

Published 2017

CADTH

Subjects: “...Canada...”

Read Now

7

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Canada...”

Read Now

8

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

9

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

10

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Canada...”

Read Now

11

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

12

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

13

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

14

High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Wells, Charlotte, Grobelna, Aleksandra
Published 2019

CADTH

Subjects: “...Canada...”

Read Now

15

High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Wells, Charlotte, Grobelna, Aleksandra
Published 2019

CADTH

Subjects: “...Canada...”

Read Now

16

Pharmacoeconomic report: Vedolizumab (Entyvio SC) Takeda Canada Inc. : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who ha...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

17

Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication: indicated in addition to standard therapy for reducing disease activity in adult patients...

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

18

CADTH Canadian Drug Expert Committee recommendation: Belimumab (Benlysta subcutaneous [SC] -- GlaxoSmithKline Inc.) : indication: systemic lupus erythematosus (SLE)

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

19

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

20

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Narrow Search